Oncoinvent
Develops new radiopharmaceutical products for better treatment options for cancer patients.
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (4 %) | 291 % | (17 %) | (25 %) | 5825 % | 25 % | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (20247 %) | (10250 %) | (15966 %) | (28276 %) | (686 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (20949 %) | (11017 %) | (17085 %) | (30215 %) | (724 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Dealroom estimates
Related Content
Oncoinvent is a pioneering company in the field of radiopharmaceuticals, dedicated to developing innovative treatment options for cancer patients. The company's lead product candidate, Radspherin, is designed to treat cancer in the peritoneal cavity, which is the space within the abdomen that houses various organs. Oncoinvent operates within the pharmaceutical and biotechnology markets, focusing on creating new radiopharmaceutical products that offer better treatment outcomes for cancer patients. The business model revolves around extensive research and development, clinical trials, and eventual commercialization of their products. Revenue is generated through the successful development and sale of these specialized cancer treatments. The company primarily serves healthcare providers, oncologists, and ultimately, cancer patients who require advanced treatment options. Oncoinvent is currently advancing through various phases of clinical trials to ensure the efficacy and safety of its products before they reach the market.
Keywords: radiopharmaceuticals, cancer treatment, peritoneal cavity, Radspherin, clinical trials, biotechnology, healthcare, oncology, innovation, pharmaceutical development.